Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin.
Publication/Presentation Date
10-1-2002
Abstract
AIMS: The purpose of this study was to determine that the administration of an angiotensin converting enzyme (ACE) inhibitor enalapril would confer protection against doxorubicin-induced experimental heart failure, and attenuate the development of left ventricular dysfunction.
METHODS: Seventeen dogs were chronically instrumented with an intracoronary catheter and received doxorubicin weekly for 4 weeks. Animals were assigned to two groups: group 1: untreated heart failure; and group 2: simultaneous enalapril administration (5 mg twice a week). Hemodynamic data were obtained at week 0 and 12. Echocardiography was performed weekly.
RESULTS: Survival improved with simultaneous enalapril administration (36% in group 1 vs. 100% in group 2, P=0.04). The increase in the left ventricular end-diastolic pressure was significantly reduced at week 12 (17+/-1 mmHg in group 1 vs. 9+/-1 mmHg in group 2, P=0.0042). The fall in left ventricular stroke work index was significantly prevented (52% in group 1 vs. 21% in group 2, P=0.006). The increase in right ventricular end-diastolic diameter was significantly reduced by enalapril prophylaxis.
CONCLUSION: Simultaneous treatment with enalapril was beneficial in the prevention of doxorubicin-induced cardiomyopathy.
Volume
4
Issue
5
First Page
583
Last Page
586
ISSN
1388-9842
Published In/Presented At
Vaynblat, M., Shah, H. R., Bhaskaran, D., Ramdev, G., Davis, W. J., 3rd, Cunningham, J. N., Jr, & Chiavarelli, M. (2002). Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. European journal of heart failure, 4(5), 583–586. https://doi.org/10.1016/s1388-9842(02)00091-0
Disciplines
Medicine and Health Sciences
PubMedID
12413500
Department(s)
Department of Pediatrics, Department of Surgery
Document Type
Article